Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Down 44.5% in April

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a significant decrease in short interest in April. As of April 30th, there was short interest totaling 147,543 shares, a decrease of 44.5% from the April 15th total of 265,805 shares. Based on an average trading volume of 38,559 shares, the days-to-cover ratio is presently 3.8 days. Approximately 0.8% of the company’s stock are short sold.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ESLA shares. Wall Street Zen upgraded shares of Estrella Immunopharma from a “sell” rating to a “hold” rating in a report on Saturday, January 31st. Weiss Ratings upgraded shares of Estrella Immunopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Finally, D. Boral Capital restated a “buy” rating and set a $8.00 price objective on shares of Estrella Immunopharma in a report on Monday, February 9th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $8.00.

Estrella Immunopharma Price Performance

NASDAQ:ESLA traded down $0.10 during midday trading on Friday, hitting $1.11. The company’s stock had a trading volume of 27,998 shares, compared to its average volume of 38,334. Estrella Immunopharma has a fifty-two week low of $0.78 and a fifty-two week high of $3.15. The firm’s 50 day moving average is $1.35 and its 200-day moving average is $1.51. The firm has a market cap of $47.36 million, a P/E ratio of -3.17 and a beta of 0.97.

Estrella Immunopharma (NASDAQ:ESLA) last issued its quarterly earnings results on Wednesday, March 18th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.17. As a group, analysts forecast that Estrella Immunopharma will post -0.39 EPS for the current year.

Hedge Funds Weigh In On Estrella Immunopharma

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC increased its holdings in Estrella Immunopharma by 1,045.7% in the 4th quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock worth $191,000 after buying an additional 111,779 shares during the period. Geode Capital Management LLC increased its holdings in Estrella Immunopharma by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock worth $171,000 after buying an additional 8,318 shares during the period. Marshall Wace LLP acquired a new position in Estrella Immunopharma in the 4th quarter worth approximately $88,000. XTX Topco Ltd increased its holdings in Estrella Immunopharma by 376.9% in the 4th quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock worth $77,000 after buying an additional 39,099 shares during the period. Finally, State Street Corp increased its holdings in Estrella Immunopharma by 93.5% in the 4th quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after buying an additional 20,900 shares during the period. Institutional investors and hedge funds own 0.35% of the company’s stock.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.